Home / Science / CAR T-Cells See Invisible Cancer Cells
CAR T-Cells See Invisible Cancer Cells
28 Apr
Summary
- CAR T-cell therapy excels in blood cancers but struggles with solid tumors.
- Tumors have varied cells, some lacking target proteins invisible to CAR T-cells.
- New study finds hidden target proteins on supposed invisible tumor cells.
Chimeric antigen receptor (CAR) T-cell therapy, a groundbreaking treatment that engineers a patient's immune cells to combat cancer, has proven highly effective against blood cancers like leukemia and lymphoma. However, its application to solid tumors, such as those found in the kidney or ovaries, has encountered significant obstacles. A primary challenge is antigen heterogeneity, where tumor cells are not uniform. Some cells display the target protein recognized by CAR T-cells, while others do not, creating a cellular patchwork.
This cellular disparity means CAR T-cells can only eliminate the visible targets, allowing the unaffected cells to survive and fuel cancer recurrence. A pivotal study, published in Science on February 26, 2026, suggests that many tumor cells previously considered invisible to CAR T-cell therapy may not be entirely so. Researchers found that these cells actually possess minute quantities of the target protein, amounts too small for current CAR T-cell therapies to detect. This discovery offers a new avenue for developing CAR T-cell treatments effective against solid tumors.
